467461-10-5

Usage

Uses

Used in Pharmaceutical Drug Synthesis:
2-[3-(Trifluoromethoxy)phenyl]ethylamine is used as a building block in the synthesis of various pharmaceutical drugs. Its unique structure allows for the creation of new compounds with potential therapeutic properties, making it a valuable component in drug discovery.
Used in Agrochemical Production:
In the agrochemical industry, 2-[3-(Trifluoromethoxy)phenyl]ethylamine is used as an intermediate in the production of organic compounds. Its versatility in chemical reactions, such as nucleophilic substitution and reductive amination, enables the synthesis of a wide range of agrochemicals with different applications.
Used in Medicinal Chemistry Research:
2-[3-(Trifluoromethoxy)phenyl]ethylamine is employed as a key intermediate in the field of medicinal chemistry. Researchers utilize its unique properties to develop novel drug candidates with potential therapeutic applications, contributing to the advancement of medical treatments and therapies.
Overall, 2-[3-(Trifluoromethoxy)phenyl]ethylamine is a significant chemical compound with diverse applications in various industries, including pharmaceuticals, agrochemicals, and medicinal chemistry. Its unique structure and versatility in chemical reactions make it an essential component in the development of new drugs and agrochemicals, as well as a valuable tool in research and drug discovery.

InChI:InChI=1/C9H10F3NO/c10-9(11,12)14-8-3-1-2-7(6-8)4-5-13/h1-3,6H,4-5,13H2

Upstream product

• 108307-56-8 2-[3-(trifluoromethoxy)phenyl]ethanenitrile 
• 52771-21-8 3-(trifluoromethoxy)benzaldehyde 

Downstream Products

• 215797-54-9 2-(3-trifluoromethoxy-phenyl)-ethylamine hydrochloride 

Relevant academic research and scientific papers

The search for new anticonvulsants in a group of (2,5-dioxopyrrolidin-1-yl)(phenyl)acetamides with hybrid structure—synthesis and in vivo/in vitro studies

Epilepsy belongs to the most common and debilitating neurological disorders with multifactorial pathophysiology and a high level of drug resistance. Therefore, with the aim of searching for new, more effective, and/or safer therapeutics, we discovered a focused series of original hybrid pyrrolidine-2,5-dione derivatives with potent anticonvulsant properties. We applied an optimized coupling reaction yielding several hybrid compounds that showed broad-spectrum activity in widely accepted animal seizure models, namely, the maximal electroshock (MES) test and the psychomotor 6 Hz (32 mA) seizure model in mice. The most potent anticonvulsant activity and favorable safety profile was demonstrated for compound 30 (median effective dose (ED50) MES = 45.6 mg/kg, ED50 6 Hz (32 mA) = 39.5 mg/kg, median toxic dose (TD50) (rotarod test) = 162.4 mg/kg). Anticonvulsant drugs often show activity in pain models, and compound 30 was also proven effective in the formalin test of tonic pain, the capsaicin-induced pain model, and the oxaliplatin (OXPT)-induced neuropathic pain model in mice. Our studies showed that the most plausible mechanism of action of 30 involves inhibition of calcium currents mediated by Cav1.2 (L-type) channels. Importantly, 30 revealed high metabolic stability on human liver microsomes, negligible hepatotoxicity, and relatively weak inhibition of CYP3A4, CYP2D6, and CYP2C9 isoforms of cytochrome P450, compared to reference compounds. The promising in vivo activity profile and drug-like properties of compound 30 make it an interesting candidate for further preclinical development.

Structure-Based Design and Discovery of New M2 Receptor Agonists

Muscarinic receptor agonists are characterized by apparently strict restraints on their tertiary or quaternary amine and their distance to an ester or related center. On the basis of the active state crystal structure of the muscarinic M2 receptor in complex with iperoxo, we explored potential agonists that lacked the highly conserved functionalities of previously known ligands. Using structure-guided pharmacophore design followed by docking, we found two agonists (compounds 3 and 17), out of 19 docked and synthesized compounds, that fit the receptor well and were predicted to form a hydrogen-bond conserved among known agonists. Structural optimization led to compound 28, which was 4-fold more potent than its parent 3. Fortified by the discovery of this new scaffold, we sought a broader range of chemotypes by docking 2.2 million fragments, which revealed another three micromolar agonists unrelated either to 28 or known muscarinics. Even pockets as tightly defined and as deeply studied as that of the muscarinic reveal opportunities for the structure-based design and the discovery of new chemotypes.

Heteroaryl carboxamide compounds

Compounds of formula I their manufacture, pharmaceutical compositions containing them and their use as medicaments.

Indole, indazole and indoline derivatives as CETP inhibitors

The present invention relates to compounds of formula (I): wherein —X—Y—, R1 to R11 and n are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prevention of diseases which are mediated by CETP inhibitors.

Pyrrolo (2.1a)dihydroisoquinolines and their use as phosphodiesterase 10a inhibitors

The present invention relates to pyrrolo[2.1-a]dihydroisoquinolines which are inhibitors of phosphodiesterase 10a and can be used for combating cancer.

Pyrrolo[2.1-a]isoquinoline derivatives

The present invention relates to pyrrolo[2.1-a]isoquinolines which are inhibitors of phosphodiesterase 10a, a process for preparing these compounds and a method of treating cancer in humans and animals by administering these compounds.